Primary axillary hyperhidrosis can be associated with significant occupational impairment, is frequently detrimental to physical and emotional well being, and can result in difficulties in personal relationships and potential social stigmatization.

First line therapies for axillary hyperhidrosis (ie deodorants) are often short acting, ineffective or not well tolerated. Surgical approaches such as excision of the sweat glands and endoscopic transthoracic sympathectomy (ETS) are an option, however can be associated with potentially serious side effects. ETS is generally not recommended for axillary hyperhidrosis because of high recurrence and high rates of compensatory sweating.

Injection therapy is an important treatment option for axillary hyperhidrosis. The therapy blocks the release of acetylcholine from peripheral cholinergic nerve terminals effectively chemically denervating the sweat glands and consequently reducing sweat gland production.

Studies have demonstrated that injection therapy is a safe and effective treatment for primary axillary hyperhidrosis. A single injection treatment can provide an average relief of hyperhidrosis of 6 to 7 months.

In addition there have been no treatment related serious adverse effects reported in clinical trials of injection therapy for hyperhidrosis even after repeated treatments. The side effects, if any, are typically mild and transient.

The excellent efficacy, safety and tolerability of injection therapy are reflected in consistently high levels of patient satisfaction, with 93% of patients satisfied at week 16 after treatment.

Injection therapy substantially reduces the marked functional impairment associated with hyperhidrosis and improves patients health related quality of life. Significant improvements are also reported in occupational functioning, time spent managing the condition, emotional well being, and functioning in interpersonal relationships and social situations.

Note: Information on this site is not a substitute for professional medical advice


Prospective Open-Label Study of Botulinum Toxin Type A in Patients with Axillary Hyperhidrosis: Effects on Functional Impairment and Quality of Life, Solish MD et al, Dermatol Surg 2005; 31:405-413